Journals / Interdisciplinary Medical Journal / 2023 / Cilt: 14 Sayı: 48

Evaluation of serum adipocytokine and interleukin-18 levels in patients with epilepsy

Pages
18–24
Publication Date
2023-04-30
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

It was found that serum adipocytokine and IL-18 concentration in epilepsy patients who received topiramate treatment decreased compared to patients who did not receive treatment, but it was not significant (p>0.05).

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Objective: Epilepsy is a neurological disease characterized by recurrent seizures.
📊
Key Findings & Data:Our aim is to investigate the relationship between serum adipocytokine and interleukin (IL)-18 levels in epilepsy patients receiving and not receiving antiepileptic therapy.
💡
Conclusion & Impact:It was found that serum adipocytokine and IL-18 concentration in epilepsy patients who received topiramate treatment decreased compared to patients who did not receive treatment, but it was not significant (p>0.05).
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Topiramate · Interleukin-18 · Adipocytokine

Abstract

Objective: Epilepsy is a neurological disease characterized by recurrent seizures. The underlying pathophysiological mechanisms in epilepsy are not fully known. Our aim is to investigate the relationship between serum adipocytokine and interleukin (IL)-18 levels in epilepsy patients receiving and not receiving antiepileptic therapy. Method: Our study was established as three groups. I: Epilepsy patients receiving antiepileptic therapy (n=30), II: Newly diagnosed epilepsy patients (n=30) and III: Control group (n=30). Serum adipocytokine and IL-18 levels were measured by enzyme-linked immunoassorbent assay method. Results: It was determined that serum adipocytokine and IL-18 levels were increased in epilepsy patients who received topiramate treatment and did not receive antiepileptic therapy compared to the control group. Serum glucose, total protein, cholesterol and albumin concentrations of patients who received antiepileptic treatment were decreased compared to the control group (p<0.001). It was found that serum adipocytokine and IL-18 concentration in epilepsy patients who received topiramate treatment decreased compared to patients who did not receive treatment, but it was not significant (p>0.05). It was found that the body mass index (BMI) ratio of epilepsy patients who received antiepileptic treatment decreased and was significant compared to the control group and the group that did not receive treatment (p<0.01). Conclusion: In our study, it was shown that serum adipocytokine and IL-18 levels were increased in epilepsy patients who received and did not receive antiepileptic therapy. Findings from this study suggest that adipocytokine and IL-18 may be useful markers for the inflammatory process of epileptogenesis.

🔖

Cite This Article

DÜNDAR, A., KILINÇ, D., YILMAZ, A., JAFAR, V., AYAN, O., ÇEVİK, M. U., ASLANHAN, H. (2023). Evaluation of serum adipocytokine and interleukin-18 levels in patients with epilepsy. Interdisciplinary Medical Journal, Cilt: 14 Sayı: 48, 18–24. https://ajindex.com/articles/931517

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (12)

  1. Hamed SA. The vascular risk associations with migraine: relation to migraine susceptibility and progression. Atherosclerosis 2009;205(1):15-22. https://doi.org/10.1016/j.atherosclerosis.2008.10.016
  2. Sachdev A, Marmura MJ. Metabolic syndrome and migraine. Front Neurol 2012 19;3:161. https://doi.org/10.3389/fneur.2012.00161
  3. Klein P, Dingledine R, Aronica E, Bernard C, Blümcke I, Boison D, et al. Commonalities in epileptogenic processes from different acute brain insults: Do they translate?Epilepsia 2018;59(1):37-66. https://doi.org/10.1111/epi.13965
  4. Liebner S, Dijkhuizen RM, Reiss Y, Plate KH, Agalliu D, Constantin G. Functional morphology of the blood-brain barrier in health and disease. Acta Neuropathol 2018;135(3):311-336. https://doi.org/10.1007/s00401-018-1815-1
  5. Maroso M, Balosso S, Ravizza T, Liu J, Aronica E, Iyer AM, et al. Toll-like receptor 4 and high-mobility group box-1 are involved in ictogenesis and can be targeted to reduce seizures. Nat Med 2010;16(4):413-9. https://doi.org/10.1038/nm.2127
  6. Klöting N, Berndt J, Kralisch S, Kovacs P, Fasshauer M, Schön MR, et al. Vaspin gene expression in human adipose tissue: association with obesity and type 2 diabetes. Biochem Biophys Res Commun 2006;339(1):430-6. https://doi.org/10.1016/j.bbrc.2005.11.039 Wada J Vaspin. A novel serpin with insulin-sensitizing effects.Expert Opin Investig Drugs 2008;17(3):327-33. https://doi.org/10.1517/13543784.17.3.327
  7. Luk T, Malam Z, Marshall JC.Pre-B cell colony-enhancing factor (PBEF)/visfatin: a novel mediator of innate immunity.J Leukoc Biol 2008;83(4):804-16. https://doi.org/10.1189/jlb.0807581
  8. Moschen AR, Kaser A, Enrich B, Mosheimer B, Theurl M, Niederegger H, et al. H.Visfatin, an adipocytokine with proinflammatory and immunomodulating properties.J Immunol 2007;178(3):1748-58. https://doi.org/10.4049/jimmunol.178.3.1748
  9. Zabel BA, Allen SJ, Kulig P, Allen JA, Cichy J, Handel TM, et al. EC.Chemerin activation by serine proteases of the coagulation, fibrinolytic, and inflammatory cascades. J Biol Chem 2005;280(41):34661-6. https://doi.org/10.1074/jbc.M504868200
  10. Takahashi M, Takahashi Y, Takahashi K, Zolotaryov FN, Hong KS, Kitazawa R,et al. Chemerin enhances insulin signaling and potentiates insulin-stimulated glucose uptake in 3T3-L1 adipocytes. FEBS Lett 2008;582(5):573-8. https://doi.org/10.1016/j.febslet.2008.01.023
  11. Leslie JA, Meldrum KK. The role of interleukin-18 in renal injury. J Surg Res 2008;145(1):170-5. https://doi.org/10.1016/j.jss.2007.03.037
  12. Meral C, Ce